Lördag 1 November | 03:28:02 Europe / Stockholm
Svenska | English

BioStock

Prenumeration

Spago: "We are really encouraged by how the trial is progressing"
2025-10-31 08:02:00

Spago Nanomedical has recently presented promising data from the ongoing phase I/IIa study Tumorad-01, where the company's candidate shows clear tumour uptake and a continued good safety profile. The results are considered proof-of-concept and mark an important step forward in the development. CEO Mats Hansen and CDO Paul Hargreaves visited BioStock's studio to talk more about the significance of the latest results, what is next in the program - and how they see the company's commercial opportunities going forward.

See the interview biostock.se:
https://biostock.se/en/2025/10/spagowe-are-really-encouraged-by-how-the-trial-is-progressing/
 
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/

Follow BioStock
Stay up to date with the latest news, upcoming events, recent videos, and podcasts! Subscribe to our newsletters at https://www.biostock.se/newsletter 
Follow BioStock on social media: LinkedIn and Facebook!  
 
About BioStock 
BioStock is the leading digital hub for the Nordic life science sector. Focusing on biotechnology, medical technology, diagnostics, and drug development, we provide daily news updates, in-depth analyses, exclusive interviews, and innovation-promoting networking events – all to keep you informed about industry developments.  
BioStock – Connecting Innovation & Capital. 

Källa MFN
Enter your email address and you will get a mail for verification you subscription to content on this page and filter


Select the time zone location for site wide time

Europe
London
Oslo
Stockholm
Helsinki

America
New York / Eastern
Chicago / Central
Los Angeles / Western

Ett mail har skickats till den givna adressen. För att logga in, klicka på "Login" i mailet för att verifiera ditt konto

Företag

Pressmeddelanden